Ion Irradiation of Sacrococcygeal Chordoma (ISAC)
Hypofractionated Ion Irradiation (Protons or Carbon Ions) of Sacrococcygeal Chordoma
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Heidelberg, Germany, 69125
- University of Heidelberg, Radiooncology, HIT
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histological confirmation of sacrococcygeal chordoma
- Karnofsky performance status ≥ 70%
- Patients age 18 - 80 years
- Macroscopic tumour (MRI)
- Written informed consent
Exclusion Criteria:
- Lack of macroscopic tumour
- Tumor extension in craniocaudal direction >16cm
- Metal implants at the level of the tumor which could influence the treatment planning
- Inability of the patient to lie quiet for at least 20 minutes (eg due to pain)
- Prior radiotherapy of the pelvic region
- Simultaneous participation in another trial that could influence the results of the study
- Active medical implants without treatment approval at the time of ion irradiation (eg, cardiac pacemaker, defibrillator)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: protons
16x4GyE protons
|
Treatment is performed using 16 x 4 GyE protons
|
|
Experimental: Carbon ions
16x4GyE carbon ions
|
Treatment is performed using 16 x 4 GyE carbon ions
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
safety and feasibility of hypofractionated irradiation in patients with sacrococcygeal chordoma using ions (protons or carbon ions) in raster scan technique
Time Frame: From date of treatment start until 12 months after treatment.
|
The evaluation is based on incidence of Grade 3-5 toxicity (NCI-CTC-AE) and/or discontinuation of the treatment for any reason.
Endpoint is the proportion of treatments without Grade 3-5 toxicity (NCI-CTC-AE) up to 12 months after treatment and/or discontinuation of the treatment for any reason
|
From date of treatment start until 12 months after treatment.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
local progression free survival (LPFS)
Time Frame: From date of treatment start until the date of first documented progression in MRI/CT scan assessed up to 12 months.
|
local progression free survival (LPFS) is determined from start of treatment until local progression in imaging (>10% size increase)
|
From date of treatment start until the date of first documented progression in MRI/CT scan assessed up to 12 months.
|
|
Overall survival (OS)
Time Frame: From date of treatment start until the date of death from any cause assessed up to 12 months.
|
Further objectives are overall survival (OS) from date of treatment start until the date of death from any cause assessed up to 12 months
|
From date of treatment start until the date of death from any cause assessed up to 12 months.
|
|
Quality of life (QoL)
Time Frame: From date of treatment start up to 12 months. Evaluation at treatment start, at the end of treatment and 12 months after treatment.
|
Quality of life (QoL) evaluated with EORTC-QLQ30 questionnaire.
|
From date of treatment start up to 12 months. Evaluation at treatment start, at the end of treatment and 12 months after treatment.
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ISAC-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.